News & Analysis on Clinical Trial Services & Contract Research And Development
By Natalie Morrison
- Last updated on
The company say her appointment will be “invaluable” to the progress of its lead molecule, beloranib, into Phase 2 clinical trials.
Prior to Zafgen, Heller was executive vice president of business development at Exelixis Pharmaceuticals.
“Zafgen is a unique pharmaceutical company with a truly innovative approach to tackling obesity at its root cause,” said Heller. “I am honored to join the exceptional team at Zafgen as the company reaches its goal of bringing its promising lead molecule, beloranib, to the market for severely obese patients.”